Biomerica (NASDAQ:BMRA) released its quarterly earnings data on Wednesday. The company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.03, Fidelity Earnings reports. Biomerica had a negative return on equity of 61.29% and a negative net margin of 47.77%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.69 million.
Shares of NASDAQ:BMRA traded up $0.14 during midday trading on Thursday, reaching $2.97. 633 shares of the company’s stock traded hands, compared to its average volume of 21,362. Biomerica has a 1 year low of $2.06 and a 1 year high of $3.69. The company has a market cap of $29.36 million, a P/E ratio of -11.42 and a beta of 1.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 3.01. The company has a fifty day simple moving average of $2.90 and a two-hundred day simple moving average of $3.02.
Several equities research analysts have commented on the company. ValuEngine lowered Biomerica from a “hold” rating to a “sell” rating in a research report on Monday, December 30th. B. Riley set a $6.30 target price on Biomerica and gave the company a “buy” rating in a research report on Monday, October 21st.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Further Reading: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.